Dr. Jeffrey Rathmell earned his bachelor’s degree from the University of Northern Iowa in 1991 in Biology with minors in both Chemistry and Physics. He received his PhD in Immunology from Stanford University in 1996 and performed postdoctoral studies at the Universities of Chicago and Pennsylvania prior to beginning as faculty at Duke University in the Departments of Pharmacology and Cancer Biology and of Immunology in 2003. Dr. Rathmell relocated to Vanderbilt in 2015 where he is the Cornelius Vanderbilt Professor of Immunobiology in the Department of Pathology, Microbiology, and Immunology and of Molecular Physiology and Biophysics and founding Director of the Vanderbilt Center for Immunobiology and co-leader of the Vanderbilt-Ingram Cancer Center Host-Tumor Interactions Program. Dr. Rathmell has been a pioneer in the fields of immunometabolism and cancer metabolism. He showed early in his career that T lymphocyte metabolism is dynamically regulated and plays a critical role to regulate the immune response. His was the first group to show that each T cell subset adopts a specific metabolic program that can be targeted to modulate cell function and fate. This work led to the development of the field of immunometabolism. The same pathways were also altered in cancer, and his work has also contributed to understanding of cancer metabolism. These metabolic changes and differential regulatory patterns point to mechanisms of disease and offer new therapeutic targets in cancer and immune-related diseases. Dr. Rathmell has been twice recognized with the Charles Randell Prize Faculty Teaching Award. Dr. Rathmell is also a Fellow of the American Association for the Advancement of Science, is a Highly Cited Researcher, and was named a scholar of the Leukemia & Lymphoma Society, the Bernard Osher Fellow of the American Asthma Foundation, and a William Paul Distinguished Innovator of the Lupus Research Alliance.